[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362800-105":59,"doc-detail-362800-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bridging-inflammation-and-oncology-the-role-and-therapeutic-potential-of-macrophage-migration-inhibitory-factor-in-lung-cancer","Bridging Inflammation and Oncology - The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer","","Lung cancer remains the leading cause of cancer mortality worldwide, and despite treatment advances, 5-year survival has improved only minimally. Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine linking inflammation with tumor growth, progression, metastasis, angiogenesis, and immune regulation. Promoter polymorphisms, including high-expression CATT repeats, alter MIF expression and risk for inflammatory, autoimmune, and malignant diseases, yet lung cancer roles remain underexplored. This review summarizes MIF’s dual roles, current preclinical therapeutic strategies, and the potential of MIF-targeted interventions to support personalized lung cancer treatment based on genetic predisposition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bridging-inflammation-and-oncology-the-role-and-therapeutic-potential-of-macrophage-migration-inhibitory-factor-in-lung-cancer/362800/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bridging-inflammation-and-oncology-the-role-and-therapeutic-potential-of-macrophage-migration-inhibitory-factor-in-lung-cancer/362800.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is lung cancer still a major clinical challenge despite treatment progress?","Question",{"text":112,"@type":113},"Lung cancer continues to cause the highest cancer-related mortality worldwide, and 5-year survival rates show minimal improvement over decades, indicating an unmet clinical need.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does MIF contribute to both inflammation and cancer progression?",{"text":117,"@type":113},"MIF promotes inflammation and supports tumor growth, progression, and metastasis by modulating the tumor microenvironment, stimulating angiogenesis, and regulating immune responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do MIF promoter polymorphisms, such as high-expression CATT repeats, play in lung cancer?",{"text":121,"@type":113},"Promoter polymorphisms influence MIF expression and susceptibility to inflammatory, autoimmune, and malignant disorders; their specific role in lung cancer remains largely unexplored, with implications for personalized strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362800,1791074746,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Review  \nBridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in  \nLung Cancer  \nMohammed Ali Selo 1,2, *, Oliviero L. Gobbo 3,4, Ismael Obaidi 1,5, Christine O’Connor 6, Darren Fayne 7, Michelle E. Armstrong 1 and Seamas C. Donnelly 1,6, *  \nAcademic Editor: Elena Levantini  \nReceived: 20 January 2026  \nRevised: 13 March 2026  \nAccepted: 16 March 2026  \nPublished: 20 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 School of Medicine, Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin, D02 R590 Dublin, Ireland; [obaidi.ismael@gmail.com](obaidi.ismael@gmail.com) (I.O.); [michelle.armstrong@tcd.ie](michelle.armstrong@tcd.ie) (M.E.A.)  \n2 Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq  \n3 School of Pharmacy and Pharmaceutical Sciences, Panoz Institute, Trinity College Dublin, D02 PN40 Dublin, Ireland; [ogobbo@tcd.ie](ogobbo@tcd.ie)  \n4 Trinity St. James’s Cancer Institute, St. James’s Hospital, D08 NHY1 Dublin, Ireland  \n5 Faculty of Pharmacy, University of Babylon, Babylon 51002, Iraq  \n6 Discipline of Clinical Medicine, Trinity Centre for Health Sciences, Tallaght University Hospital, D24 NR0A Dublin, Ireland; [christine.oconnor@tuh.ie](christine.oconnor@tuh.ie)  \n7 School of Chemical Sciences, DCU Life Sciences Institute, Dublin City University, D09 V209 Glasnevin, Ireland; [darren.p.fayne@dcu.ie](darren.p.fayne@dcu.ie)  \n* Correspondence: [selom@tcd.ie](selom@tcd.ie) (M.A.S.); [seamas.donnelly@tcd.ie](seamas.donnelly@tcd.ie) (S.C.D.)  \nAbstract  \nLung cancer is the leading cause of cancer-related mortality worldwide, accounting for more deaths than any other malignancy. Despite advances in treatment, it remains highly lethal, with 5-year survival rates showing minimal improvement over the past several decades, highlighting a critical unmet clinical need. Macrophage Migration Inhibitory Factor (MIF) is a multifunctional cytokine that contributes to inflammation and cancer, promoting tumor growth, progression, and metastasis through modulation of the tumor microenvironment, stimulation of angiogenesis, and regulation of immune responses. Polymorphisms in the promoter region of MIF, such as high-expression CATT repeats, influence MIF expression and susceptibility to a range of inflammatory, autoimmune, and malignant disorders, yet their role in lung cancer remains largely unexplored. Therapeutic strategies targeting MIF, including small-molecule inhibitors, antibodies, and peptide-based agents, have shown promise in preclinical models, although their clinical translation is still limited. This review discusses the dual role of MIF in inflammation and oncology, summarizes current therapeutic developments, and emphasizes the potential of MIF-targeted interventionsin lung cancer. It discusses the significance of genetic predisposition, particularly highexpression MIF alleles, in guiding personalized treatment strategies for lung cancer and identifying patients who may derive benefit from MIF inhibition.  \nKeywords: tumor; tautomerase; macrophage migration inhibitory factor (MIF) polymorphisms; CATT repeats; targeted therapy; oxidized MIF (oxMIF); metastasis; survival rate  \n1. Introduction  \nLung cancer is one of the most aggressive and lethal malignancies worldwide, consistently ranking among the leading cancers in both incidence and mortality. It has remained the leading cause of cancer-related deaths worldwide since 1985, with both incidence and  \nmortality steadily rising, and the high fatality rate causing mortality to mirror incidence [1] . Globally, in 2008, it accounted for 1.6 million new cases (13% of all cancers) and 1.4 million deaths (18% of cancer-related deaths), ranking first in incidence and mortality among men and fourth in incidence and second in mortalit","cbCaisHt1fjyhQFp","https://ap.wps.com/l/cbCaisHt1fjyhQFp","pdf",1722929,34,"English","# Abstract\n# Introduction\n# Macrophage Migration Inhibitory Factor (MIF) in Inflammation and Oncology\n## Mechanisms linking MIF to tumor microenvironment and metastasis\n## Genetic polymorphisms and lung cancer risk\n# Therapeutic Targeting of MIF\n## Small-molecule inhibitors, antibodies, and peptide-based agents\n## Translational status and therapeutic potential","[{\"question\":\"Why is lung cancer still a major clinical challenge despite treatment progress?\",\"answer\":\"Lung cancer continues to cause the highest cancer-related mortality worldwide, and 5-year survival rates show minimal improvement over decades, indicating an unmet clinical need.\"},{\"question\":\"How does MIF contribute to both inflammation and cancer progression?\",\"answer\":\"MIF promotes inflammation and supports tumor growth, progression, and metastasis by modulating the tumor microenvironment, stimulating angiogenesis, and regulating immune responses.\"},{\"question\":\"What role do MIF promoter polymorphisms, such as high-expression CATT repeats, play in lung cancer?\",\"answer\":\"Promoter polymorphisms influence MIF expression and susceptibility to inflammatory, autoimmune, and malignant disorders; their specific role in lung cancer remains largely unexplored, with implications for personalized strategies.\"}]","Bridging Inflammation and Oncology - The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer | PDF",1790149120,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b928c921702bc1e3e949bef9e3971999.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bae66dcaa1bdba44350012a619702106.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8ca57895f7bff4dc095ee4044254ea5.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73499ebd30dc39cde6668a6ff29378ad.webp",980,1385]